Sangrose Laboratories Profile
Key Indicators
- Authorised Capital ₹ 9.00 M
as on 21-12-2024
- Paid Up Capital ₹ 3.83 M
as on 21-12-2024
- Company Age 28 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.87 Cr
as on 21-12-2024
- Satisfied Charges ₹ 1.52 Cr
as on 21-12-2024
- Revenue -28.66%
(FY 2023)
- Profit -12.44%
(FY 2023)
- Ebitda -22.71%
(FY 2023)
- Net Worth 16.58%
(FY 2023)
- Total Assets 7.36%
(FY 2023)
About Sangrose Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 9.00 M and a paid-up capital of Rs 3.83 M.
The company currently has active open charges totaling ₹1.87 Cr. The company has closed loans amounting to ₹1.52 Cr, as per Ministry of Corporate Affairs (MCA) records.
Alexander Kunjummen, Chackalamuryil Joseph, George Mathew, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231KL1996PTC010099
- Company No.
010099
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Mar 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- LocationAlappuzha, Kerala
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sangrose Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alexander Kunjummen  | Managing Director | 01-Mar-1996 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chackalamuryil Joseph | Director | 05-Sep-2001 | Current |
| George Mathew | Director | 01-Mar-1996 | Current |
| Thomas Alexander | Whole-Time Director | 25-Feb-2002 | Current |
Financial Performance of Sangrose Laboratories.
Sangrose Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 28.66% decrease. The company also saw a substantial fall in profitability, with a 12.44% decrease in profit. The company's net worth Soared by an impressive increase of 16.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sangrose Laboratories?
In 2023, Sangrose Laboratories had a public holding of 18.27%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sangros Drugchem Private LimitedActive 29 years 6 daysAlexander Kunjummen and Thomas Alexander are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 17 Jan 1994 | ₹1.87 Cr | Open |
Kerala Financial Corporation Creation Date: 03 Sep 2013 | ₹7.68 M | Satisfied |
Kerala Financial Corporation Creation Date: 01 Jul 2003 | ₹7.50 M | Satisfied |
How Many Employees Work at Sangrose Laboratories?
Sangrose Laboratories has a workforce of 128 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sangrose Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sangrose Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
